Suchergebnisse - "Kayser, Sabine"

PubPharm (127)

81

Primair hyperaldosteronisme en hypertensie

enthalten in: Huisarts en wetenschap | 2015

von Käyser, S.

82

Primair hyperaldosteronisme en hypertensie

enthalten in: Huisarts en wetenschap | 2015

von Käyser, S.

83

Minimal residual disease in acute myeloid leukemia : current status and future perspectives

enthalten in: Current hematologic malignancy reports | 21 May 2015

von Kayser, S.

84

Minimal residual disease-directed therapy in acute myeloid leukemia

enthalten in: Blood | 28 January 2015

von Kayser, S.

85

Minimal residual disease-directed therapy in acute myeloid leukemia

enthalten in: Blood | 2015

von Kayser, S. | Schlenk, R. | Grimwade, D. | +2

86

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

enthalten in: British journal of haematology | 2015

von Fiedler, W. | Kayser, S. | Kebenko, M. | +13

87

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

enthalten in: Blood | 2014

von Schlenk, R. | Kayser, S. | Bullinger, L. | +23

CommentIn: Blood. 2014 Nov 27;124(23):3341-2. - PMID 25431476

88

Differential impact of allelic ratio and insertion site in FLT3-ITDpositive AML with respect to allogeneic transplantation

enthalten in: Blood | 2014

von Schlenk, R. | Kayser, S. | Bullinger, L. | +22

89

Bronchodilator safety in chronic obstructive pulmonary disease : time to focus?

enthalten in: JAMA internal medicine | 2014

von van Dijk, W. | Käyser, S.

CommentOn: JAMA Intern Med. 2013 Jul 8;173(13):1175-85. - PMID 23689820

90

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

enthalten in: Leukemia & lymphoma | 2014

von Kayser, S. | Levis, M.